Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
News about Merit Medical Systems, Inc. (NASDAQ: MMSI) focuses on its role as a healthcare technology and medical device company engaged in the development, manufacture, and distribution of proprietary devices for interventional, diagnostic, and therapeutic procedures. Company announcements highlight activity in cardiology, radiology, oncology, critical care, and endoscopy, as well as updates on its Cardiovascular and Endoscopy segments.
Investors and healthcare professionals following MMSI news will see earnings releases, financial guidance updates, and segment performance details reported through quarterly results and Form 8-K filings. These updates often include net sales by segment, constant currency revenue figures, and non-GAAP financial measures, along with management commentary on operating performance and outlook.
Merit’s news flow also features product and clinical milestones. The company has issued releases on the WRAPSODY Cell-Impermeable Endoprosthesis (CIE), including regulatory approvals, commercialization strategies, and 24‑month efficacy results from the WAVE trial and related registries in hemodialysis patients. Additional coverage includes updates on the SCOUT Radar Localization system in breast cancer care and milestones in its global utilization.
Another key theme in MMSI news is portfolio expansion through acquisitions. Merit has announced transactions such as the asset purchase agreement to acquire the C2 CryoBalloon device and related technology for gastrointestinal disorders and has reported the closing of this acquisition in subsequent filings. These items provide insight into how the company is broadening its Endoscopy portfolio and entering or expanding in specific therapeutic markets.
Governance and leadership developments, including CEO transitions and changes in board roles, are disclosed via press releases and Form 8-K filings and form an important part of the company’s news record. For readers tracking MMSI, this news page aggregates updates on financial performance, product developments, acquisitions, regulatory milestones, and leadership changes, offering a centralized view of the company’s publicly reported activities.
Merit Medical Systems (NASDAQ: MMSI) announced its participation in the 2021 SVB Leerink Global Healthcare Conference.
The conference will be held virtually on February 25, 2021, at 2:20 p.m. ET. CEO Fred P. Lampropoulos and CFO Raul Parra will present and host one-on-one meetings.
Founded in 1987, Merit specializes in manufacturing disposable medical devices for various medical fields, employing approximately 6,000 individuals worldwide.
Merit Medical Systems, a leading manufacturer of disposable medical devices, announced participation in two upcoming virtual investor conferences. On January 13, at 2:00 p.m. ET, CEO Fred P. Lampropoulos and CFO Raul Parra will present at the 23rd Annual Needham Growth Conference. The following day, January 14, at 2:30 p.m. ET, they will host a fireside chat at the ICR Conference 2021. Both events will include virtual one-on-one meetings with investors.
SOUTH JORDAN, Utah, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI) will hold an investor call today to discuss multi-year financial targets from 2020 to 2023. Key targets include a compound annual growth rate (CAGR) of 5%-7% in revenue, a GAAP operating margin of 13.7%-17.0%, and a non-GAAP operating margin of 18%-21%. The company estimates 2020 net revenue between $950 million and $959 million, a decline from $994.9 million in 2019. GAAP net loss is forecasted between $(11.8) million and $(15.0) million.
Merit Medical Systems reports Q3 2020 revenue of $244.0 million, a 0.4% increase from Q3 2019. Core revenue fell (0.1)% on a constant currency basis, while GAAP loss per share improved to $(0.05), from $(0.06). Non-GAAP EPS rose 50% to $0.42. GAAP gross margin decreased from 42.8% to 41.8%, but non-GAAP gross margin fell from 48.1% to 47.0%. Cash on hand increased to $44.6 million, with long-term debt down to $358 million. Fiscal 2020 revenue guidance is estimated at $950-$959 million, reflecting a 3.5%-4.5% annual decline.
Merit Medical Systems (NASDAQ: MMSI) announced a settlement with the U.S. Department of Justice and Health and Human Services, opting to pay $18 million to avoid litigation costs. The settlement does not imply wrongdoing, as Merit denies the allegations. The company aims to refocus on its core mission of customer service in healthcare.
Founded in 1987, Merit specializes in proprietary disposable medical devices for various medical procedures, serving hospitals globally with a workforce of around 6,000 personnel across numerous locations.
Merit Medical Systems (NASDAQ: MMSI) announces financial results for Q3 2020 on October 28, 2020, after market close. An investor call will follow on November 10, 2020, to introduce multi-year financial targets for growth and profitability. The company, a major player in medical devices for cardiology, oncology, and other sectors, will host a Q&A session during the investor call, accessible via phone and live webcast.
Merit Medical Systems (NASDAQ: MMSI) announced participation in four investment conferences in September 2020. On September 9, CEO Fred P. Lampropoulos and CFO Raul Parra will engage in one-on-one meetings at the Barrington Research Virtual Fall Investment Conference. The following day, Lampropoulos will also host meetings at the Wells Fargo Virtual Healthcare Conference. Parra is set to present at the Baird's Global Healthcare Conference on September 10 and will conduct meetings. Lastly, both executives will present at Sidoti’s Fall 2020 Virtual Investor Conference on September 24.
Merit Medical Systems reported Q2 2020 revenue of $218.4 million, a 14.5% decrease from the previous year. The company faced a GAAP loss per share of $(0.34), down from $0.12 in Q2 2019. Non-GAAP EPS was $0.31, compared to $0.42 last year. Their free cash flow for the quarter was $32 million. Merit encountered challenges during the COVID-19 pandemic but continued operations as an essential provider. The company received CE mark for the WRAPSODY™ Stent and FDA approval for the WAVE trial, indicating potential growth prospects despite current uncertainties.
Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its financial results for Q2 2020 after the market closes on July 29, 2020. Following this, an investor conference call is scheduled for the same day at 5:00 p.m. Eastern. Interested parties can participate by calling (844) 578-9672 domestically or (508) 637-5656 internationally, and a live webcast will be available on their website. Founded in 1987, Merit specializes in disposable medical devices used in various medical fields, employing around 6,000 people globally.
Merit Medical Systems (NASDAQ: MMSI) has reached an agreement with the Department of Justice to resolve its marketing practices investigation, expecting to pay $18 million while denying the allegations. CEO Fred P. Lampropoulos stated that this resolution is beneficial for the business, allowing the company to refocus on customer service. The final settlement details will be released once the documents are finalized. Merit, established in 1987, specializes in developing and distributing disposable medical devices across various medical fields, employing around 6,000 individuals globally.
FAQ
What is the current stock price of Merit Med Sys (MMSI)?
What is the market cap of Merit Med Sys (MMSI)?
